Balancing the need for access with the imperative for empirical evidence of benefit and risk

JAMA - Journal of the American Medical Association

Volumn 318, Issue 7, 2017, Pages 614-616

  Califf, Robert M ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; RISK;

HUMANS; RISK;

EID: 85027863984     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.9412     Document Type: Editorial

References (13)

1. Naci H, Smalley KR, Kesselheim AS. Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration. JAMA. doi:10.1001/jama.2017.9415
2. Zheng SY, Dhruva SS, Redberg RF. Characteristics of clinical studies used for US Food and Drug Administration approval of high-risk medical device supplements. JAMA. doi:10.1001 /jama.2017.9414
3. US Food and Drug Administration. Guidance for industry: expedited programs for serious conditions—drugs and biologics. May 2014. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf. Accessed July 19, 2017.
4. US Food and Drug Administration. Modifications to devices subject to premarket approval (PMA)—the PMA supplement decision: when to submit a panel-track PMA supplement. https://www.fda.gov/RegulatoryInformation/Guidances/ucm089274.htm#4b. Accessed July 19, 2017.
5. New Drugs, 21 USC §355 (2016).
6. Sherman RE, Davies KM, Robb MA, Hunter NL, Califf RM. Accelerating development of scientific evidence for medical products within the existing US regulatory framework. Nat Rev Drug Discov. 2017;16(5):297-298.
7. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125(7):605-613.
8. Bhatt DL, Kandzari DE, O’Neill WW, et al; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393-1401.
9. US Food and Drug Administration. Centers of Excellence in Regulatory Science and Innovation (CERSI). https://www.fda.gov/scienceresearch/specialtopics/regulatoryscience/ucm301667.htm. Accessed July 21, 2017.
10. National Center for Advancing Translational Sciences, National Institutes of Health. Clinical and Translational Science Awards (CTSA) Program. https://ncats.nih.gov/ctsa. Accessed July 21, 2017.
11. National Institutes of Health. Health Care Systems Research Collaboratory. https://www.nihcollaboratory.org. Accessed July 24, 2017.
12. Patient-Centered Outcomes Research Institute. National Patient-Centered Clinical Research Network. http://www.pcornet.org. Accessed July 24, 2017.
13. Shuren J, Califf RM. Need for a National Evaluation System for Health Technology. JAMA. 2016;316(11):1153-1154.